Jianhua Yu mainly investigates Cancer research, Immunology, Cell biology, Interleukin 12 and Interleukin 21. Jianhua Yu works in the field of Cancer research, focusing on Myeloid leukemia in particular. His studies in Myeloid leukemia integrate themes in fields like Molecular biology, Leukemia, microRNA and Clinical trial.
His Immunology research is multidisciplinary, relying on both Lymphopoiesis and Cytotoxicity. His research in Cell biology intersects with topics in Cell, Cellular differentiation, Transcription factor, Innate immune system and NAD+ kinase. The study incorporates disciplines such as Interleukin, Natural killer cell and CD40 in addition to Interleukin 12.
The scientist’s investigation covers issues in Cancer research, Immunology, Cell biology, Immune system and Molecular biology. His work carried out in the field of Cancer research brings together such families of science as Cancer cell, Cancer, Oncolytic virus and Interferon gamma. His Cell biology research incorporates themes from Natural killer cell, Interleukin 12, Cell and Interleukin 21.
His Cell research integrates issues from Innate lymphoid cell and Cell growth. His Immune system research includes themes of Cytotoxic T cell, NF-κB and Cytotoxicity. As part of one scientific family, Jianhua Yu deals mainly with the area of Molecular biology, narrowing it down to issues related to the Myeloid leukemia, and often Myeloid.
His primary scientific interests are in Cancer research, Cell biology, Immune system, Cell and Antibody. Cancer research and Population are two areas of study in which Jianhua Yu engages in interdisciplinary work. The various areas that he examines in his Cell biology study include Receptor, Granzyme B, Downregulation and upregulation and Cell growth.
His Immune system study frequently draws parallels with other fields, such as Natural killer cell. His research integrates issues of In vivo, Immunophenotyping, Innate lymphoid cell and Cytolysis in his study of Cell. His work in Antibody covers topics such as Antigen which are related to areas like NKG2D, Chimeric antigen receptor and Immunity.
Jianhua Yu mainly focuses on Cancer research, Immune system, Cell biology, Antibody and Cell growth. His Cancer research research is multidisciplinary, incorporating perspectives in Cancer cell, Cancer, Oncolytic virus, Azoxymethane and Immunity. His Immune system research is multidisciplinary, incorporating elements of Complication, Mesenchymal stem cell and Graft-versus-host disease.
His Cell biology research incorporates elements of Granzyme B and Multiple drug resistance. His Antibody research includes elements of Protein subunit and Antigen. In his study, Viral entry, Virus and Herpes simplex virus is inextricably linked to Innate immune system, which falls within the broad field of Cell growth.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
Ramiro Garzon;Shujun Liu;Muller Fabbri;Zhongfa Liu.
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Don M. Benson;Courtney E. Bakan;Anjali Mishra;Craig C. Hofmeister.
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Shu Hao Hsu;Bo Wang;Janaiah Kota;Jianhua Yu.
Journal of Clinical Investigation (2012)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
Giulia Fulci;Laura Breymann;Davide Gianni;Kazuhiko Kurozomi.
Proceedings of the National Academy of Sciences of the United States of America (2006)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianhong Chu;Youcai Deng;Don M. Benson;Shun He.
Curcumin is a potent DNA hypomethylation agent.
Zhongfa Liu;Zhiliang Xie;William Jones;Ryan E. Pavlovicz.
Bioorganic & Medicinal Chemistry Letters (2009)
Location and cellular stages of natural killer cell development.
Jianhua Yu;Aharon G. Freud;Michael A. Caligiuri.
Trends in Immunology (2013)
Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia
Shujun Liu;Lai Chu Wu;Jiuxia Pang;Ramasamy Santhanam.
Cancer Cell (2010)
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets
Jianhua Yu;Hsiaoyin Charlene Mao;Min Wei;Tiffany Hughes.
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins;Courtney E. Bakan;Gina D. Swartzel;Craig C. Hofmeister.
Cancer Immunology, Immunotherapy (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: